1/5

Favipiravir Avigan for Conoravirus Medicine Cure Raw Material
$0.00
- FOB Price:
- Negotiable | Get Latest Price
- Order Quantity:
- 1 Set / Sets
- Supply Ability:
- 1000 Set / Sets per Month
- Port:
- shanghai
- Payment Terms:
- T/T L/C D/P D/A Credit Card PayPal Cash Escrow Other
- Delivery Detail:
- 5 days
Hot in store
Product Details
Product Name: Favipiravir Avigan for Conoravirus Medicine Cure Raw Material Purity: >99% State: Solid Suitable for: Elderly, Children, Adult Certification: ISO 9001 Customized: Non-Customized Powder: Yes Origin: China Product Description Raw Material Favipiravir CAS 259793-96-9 T-705 Avigan for Conoravirus Medicine Cure Product nameFavipiravirCAS NO.259793-96-9CategoryPharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.Purity99%Appearanceyellow powderShelf life2 yearsUsageFavipiravir is an antiviral drug.StorageFavipiravir should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.NoteFavipiravir for R&D use only.Favipiravir,alsoknownasT1106,itisapyrazinecarboxamidederivative.Favipiravirisactiveagainstinfluenzaviruses,WestNilevirus,yellowfevervirus,footandmouthdiseasevirusaswellasotherflaviviruses,arenaviruses,bunyavirusesandalphaviruses.ActivityagainstenterovirusesandRiftValleyfevervirushasalsobeendemonstrated.ThemechanismofitsactionsisthoughttoberelatedtotheselectiveinhibitionofviralRNAdependentRNApolymerase.FavipiravirdoesnotinhibitRNAorDNAsynthesisinmammaliancellsandisnottoxictothemIn2014,favipiravirwasapprovedinJapanforstockpilingagainstinfluenzapandemics.EbolavirusdiseaseThedrugappearstobeeffectiveinamousemodelofEbolavirusdisease,butitsefficacyagainsthumanEbolainfectionisunproved.Duringthe2014WestAfricaEbolavirusoutbreak,itwasreportedthataFrenchnursewhocontractedEbolawhilevolunteeringforMSFinLiberiarecoveredafterreceivingacourseoffavipiravir.AclinicaltrialinvestigatingtheuseoffavipiraviragainstEbolavirusdiseasewasstartedinGuéckédou,Guinea,duringDecember2014.PreliminaryresultsshowedadecreaseinmortalityrateinpatientswithlowtomoderatelevelsofEbolavirusintheblood,butnoeffectonpatientswithhighlevelsofthevirus,agroupatahigherriskofdeath.
Contact with Supplier
Recommend product